Work at Zhuhai United Laboratories Co. Ltd. has led to the identification of new apelin receptor (APLNR) agonists reported to be useful for the treatment of diabetes, heart failure, muscle atrophy, chronic kidney disease, pulmonary hypertension, amyotrophic lateral sclerosis, atherosclerosis and Alzheimer’s disease, among others.
Researchers from Renbio Inc. and Louisiana State University investigated the delivery of plasmid DNA encoding new glucagon-like peptide-1(GLP-1)-based biologics with MYO (Make Your Own) technology as a new therapeutic strategy. This approach ensures the continuous production of GLP-1-based biologics for an extended period, overcoming the need for weekly dosing.
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome proliferator activated receptors (PPAR α/γ/δ). GLP-1-GIP-Lani enables targeted delivery of the PPAR agonist to cells that express incretin receptors, enhancing weight loss, improving glucose control and reducing inflammation in obese mice. In these models, it surpassed the effects of GLP-1 receptor agonists such as semaglutide and GLP-1-GIP co-agonists such as tirzepatide in reducing body weight, improving glycemic control and enhancing metabolic outcomes during active treatment.
Pfizer Inc. has discovered new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity.
Pfizer Inc. has patented new gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be potentially useful for the treatment of type 2 diabetes and obesity.
Work at Crinetics Pharmaceuticals Inc. has led to the identification of new thyroid-stimulating hormone (thyrotropin) receptor (TSHR) antagonists designed for use in the treatment of hyperthyroidism.
In previous work, researchers from Kawasaki Medical School and collaborating institutions engineered a modified HEXB construct, modHexB, to improve GM2 ganglioside (GM2) recognition and GM2-activating protein (GM2A) interaction. The team has now combined these previous advancements to develop a new gene therapy strategy for Sandhoff disease.
Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and gastric inhibitory polypeptide receptor (GIPR) agonists that are potentially useful for the treatment of dyslipidemia, hepatic steatosis, metabolic syndrome, obesity and type 2 diabetes.
Hinova Pharmaceuticals Inc. has synthesized prodrugs of orforglipron (a glucagon-like peptide 1 receptor [GLP-1R] agonist) for the potential treatment of diabetes, obesity, hypertension, arteriosclerosis, cerebral infarction, arthritis, polycystic ovary syndrome and Parkinson’s disease, among others.
RSS
